Shanghai Junshi Biosciences Co Receita A/A
Qual é o Receita A/A de Shanghai Junshi Biosciences Co?
O Receita A/A de Shanghai Junshi Biosciences Co., Ltd. é -23.54%
Qual é a definição de Receita A/A?
O crescimento anual da receita nos últimos 3 anos é o crescimento da receita de um ano para o próximo nos últimos 3 anos.
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
Receita A/A de empresas na Setor Health Care em OTC em comparação com Shanghai Junshi Biosciences Co
O que Shanghai Junshi Biosciences Co faz?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Empresas com receita a/a semelhantes a Shanghai Junshi Biosciences Co
- Qingdao Haier Biomedical Co tem Receita A/A de -23.64%
- Vanda Pharmaceuticals Inc tem Receita A/A de -23.63%
- Principal Inc tem Receita A/A de -23.61%
- 17 Education & Technology tem Receita A/A de -23.58%
- Columbia , Inc tem Receita A/A de -23.57%
- Heartland USA tem Receita A/A de -23.55%
- Shanghai Junshi Biosciences Co tem Receita A/A de -23.54%
- Yangarra Resources tem Receita A/A de -23.54%
- Amarin Corp tem Receita A/A de -23.53%
- GMR Infrastructure tem Receita A/A de -23.51%
- Eastern Treads tem Receita A/A de -23.50%
- Brookfield Property Partners L.P tem Receita A/A de -23.50%
- Mesoblast tem Receita A/A de -23.48%